Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Perrigo Company PLC (NYSE:PRGO)

96.61
Delayed Data
As of May 27
 +0.41 / +0.43%
Today’s Change
84.85
Today|||52-Week Range
198.42
-33.23%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$13.8B

Company Description

Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences. The CHC segment includes the company's former segments, which are the Nutritionals and Israel Pharmaceuticals and Diagnostics business. The BCH segment consists of the Omega business. The Prescription Pharmaceuticals includes the Rx Pharmaceuticals business. The Specialty Sciences segment comprises of the assets, which focuses on the treatment of multiple sclerosis. The company was founded in 1887 and is headquartered in Dublin, Ireland.

Contact Information

Perrigo Co. Plc
Treasury Building
Dublin Dublin 00200
P:(531) 709-4000
Investor Relations:
(269) 686-3373

Employees

Shareholders

Other institutional40.60%
Individual stakeholders4.28%
Mutual fund holders38.49%

Top Executives

John T. HendricksonPresident & Chief Executive Officer
Judy L. BrownChief Financial Officer & Executive Vice President
Thomas FarringtonChief Information Officer & Executive VP
Todd W. KingmaSecretary, Executive VP & General Counsel
Sharon KochanExecutive Vice President & GM-International